Bromocriptine — an old drug in a new formulation for the effective treatment of type 2 diabetes

Quick-release bromocriptine mesylate was approved by the Food and Drug Administration (FDA) in May 2009, for the treatment of type 2 diabetes (T2DM). The quick-release formulation of bromocriptine (bromocriptine- QR; Cycloset) represents a novel therapeutic option in T2DM by targeting centrally mediated pathways of glucose metabolism, effecting in reducing plasma glucose, triglycerides, free fatty acid (FFA) levels and eventually cardiovascular events. Randomized controlled trials have shown that bromocriptine- QR lowers glycated hemoglobin by 0.4– –0.8% either as monotherapy or in combination with other anti-diabetes medications. Bromocriptine-QR mechanism of action, unique formulation, clinical efficacy and safety, proves it to be a great alternative to current treatments for type 2 diabetes. (Diabet. Prakt. 2011; 12, 5: 175–179)Quick-release bromocriptine mesylate was approved by the Food and Drug Administration (FDA) in May 2009, for the treatment of type 2 diabetes (T2DM). The quick-release formulation of bromocriptine (bromocriptine- QR; Cycloset) represents a novel therapeutic option in T2DM by targeting centrally mediated pathways of glucose metabolism, effecting in reducing plasma glucose, triglycerides, free fatty acid (FFA) levels and eventually cardiovascular events. Randomized controlled trials have shown that bromocriptine- QR lowers glycated hemoglobin by 0.4– –0.8% either as monotherapy or in combination with other anti-diabetes medications. Bromocriptine-QR mechanism of action, unique formulation, clinical efficacy and safety, proves it to be a great alternative to current treatments for type 2 diabetes. (Diabet. Prakt. 2011; 12, 5: 175–179